�y��vlog

"This study builds on the standard-of-care neoadjuvant chemoimmunotherapy treatment and supports perioperative nivolumab as an effective approach that reduces the risk of lung cancer relapse," said principal investigator Tina Cascone, M.D.,

These findings add to recent success seen with neoadjuvant nivolumab plus chemotherapy in NSCLC.

"Looking ahead, it will be critical to identify patient and disease characteristics that will tell us who can potentially be cured with neoadjuvant chemoimmunotherapy only and who will benefit from more intensified treatment strategies."

Heymach explained that future studies must determine which patients receive the most benefit from neoadjuvant therapy and may be able to avoid further treatment as well as those who remain at high risk of recurrence and may require more intensive adjuvant regimens.

MD Anderson is engaged in longstanding multidisciplinary efforts to use neoadjuvant treatments to improve outcomes for patients.